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Significance statement of key findings 
In this prospective study we have simultaneously, under controlled conditions, established 
the biological and analytical variability of glomerular filtration rate (GFR) and estimates of 
GFR in patients with moderate chronic kidney disease. Variability of estimates of GFR 
using the Modification of Diet in Renal Disease (MDRD) Study and Chronic Kidney 
Disease Epidemiology (CKD-EPI) equations were similar to each other, but slightly lower 
than that of GFR measured using iohexol clearance. Consequently estimated GFR would 
need to decline by approximately 14% for that change to be considered significant with 
95% certainty, compared to an approximately 18% decline in measured GFR for the same 
degree of certainty. The data presented can be used to assist an objective understanding 
of GFR changes in clinical practice. 
Abstract  
 
When assessing changes in glomerular filtration rate (GFR) it is important to differentiate 
pathological change from intrinsic biological and analytical variation. GFR is measured 
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using complex reference methods (e.g. iohexol clearance). In clinical practice 
measurement of creatinine and cystatin C is used in equations (e.g. Modification of Diet in 
Renal Disease [MDRD] or Chronic Kidney Disease Epidemiology Collaboration [CKD-
EPI]) to provide estimated GFR. We studied biological variability of measured and 
estimated GFR in twenty nephrology outpatients (10 male, 10 female; median age 71, 
range 50-80 years) with moderate CKD (GFR 30-59 mL/min/1.73 m2). Patients underwent 
weekly GFR measurement by iohexol clearance over four consecutive weeks. 
Simultaneously GFR was estimated using the MDRD, CKD-EPIcreatinine, CKD-EPIcystatinC 
and CKD-EPIcreatinine+cystatinC equations. Within-subject biological variation (CVI) expressed 
as a percentage [95% CI] for the MDRD (5.0% [4.3-6.1]), CKD-EPIcreatinine (5.3% [4.5-6.4]), 
CKD-EPIcystatinC (5.3% [4.5-6.5]), and CKD-EPIcreatinine+cystatinC (5.0% [4.3-6.2]) equations 
were broadly equivalent. CVI values for MDRD and CKD- EPIcreatinine+cystatinC were lower 
(p=0.027 and p=0.022 respectively) than that of measured GFR (6.7% [5.6-8.2]). 
Reference change values (RCV), the point at which a true change in a biomarker in an 
individual can be inferred to have occurred with 95% probability were calculated: using the 
MDRD equation, positive and negative RCVs were 15.1% and 13.1% respectively. If an 
individual’s baseline MDRD estimated GFR (mL/min/1.73 m2) was 59, significant 
increases or decreases would be to values >68 or <51 respectively. Within-subject 
variability of estimated GFR is lower than measured GFR. RCVs can be used to 
understand GFR changes in clinical practice. 
 
Keywords: biological variation, creatinine, cystatin C, glomerular filtration rate, iohexol, 
kidney disease, MDRD, CKD-EPI 
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Introduction 
 
Chronic kidney disease (CKD) is prevalent in the general population1-4 and is commonly 
identified using estimation of glomerular filtration rate (GFR). The aim of disease detection 
is to make decisions on therapeutic interventions, and to identify and manage those most 
likely to progress to kidney failure and/or those at high risk of morbidity and mortality. The 
ability of tests to identify which individuals with CKD are at high risk of progressive or fatal 
disease is a crucial issue. However, what constitutes progressive kidney disease has 
been variably defined. Furthermore, a significant problem has been the ability of GFR 
measurements and estimations to identify progression of kidney disease against 
background age-related change in GFR and the biological and measurement variability of 
both reference and estimated GFR.5 
 
Ideally, for accuracy GFR would be measured using either inulin clearance or one of 
several surrogate ‘reference methods’ in specialist clinical use (e.g. plasma clearance of 
iothalamate, iohexol or 51Cr ethylenediaminetetraacetic acid). However, these techniques 
are somewhat complex and time-consuming. Pragmatic estimates of GFR, based on 
serum creatinine or cystatin C measurement, or both, are widely used. As with any 
physiological measurement, GFR, whether measured or estimated, has an intrinsic within-
subject biological variability (CVI). Knowledge of this variability is critical to appreciation of 
disease-related change. Using a variety of reference markers, earlier studies have 
reported within-subject coefficients of variation (CV%) for the biological variation of GFR 
ranging between 5.5% and 12.1%.6-12 Whilst forming a useful basis for comparison, many 
of these previous estimates did not follow an appropriate construct for a biological 
variation study and do not permit comparison of measured and estimated GFR.13 
 
An understanding of biological variation of disease markers is essential to the 
interpretation of changes in response to disease events. Critical evaluation of the 
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significance of changes in results obtained on analysis of serial specimens can be 
performed only by consideration of CVI and analytical (CVA) variation.14 These data 
enable the derivation of the reference change value (RCV), the point at which a true 
change in a biomarker in an individual can be inferred to have occurred with a stated 
degree of probability: typically 95% probability is chosen as this is conventionally regarded 
as significant.14, 15  
 
The aim of the present study is to define under standardised conditions the normal 
biological variability of measured GFR and hence derive mathematically the RCV. A 
subsidiary question is whether the CVI and RCV are the same if estimated instead of 
measured GFR is used.  
 
Results 
 
Characteristics of the study subjects are shown in Table 1. Medications were held 
constant during the four weeks of the study, except that two patients received a one week 
course of amoxicillin (500 mg tds) due to chest infection.  
 
All 20 patients attended all four iohexol clearance procedures excepting one patient who 
missed one appointment. Results from five iohexol clearances (five separate patients) 
were excluded before analysis, as the dose given was not fully administered or it was 
given subcutaneously. Application of Cochran and Reed’s tests led to the exclusion of 
between one and three duplicate measurements for measured or estimated GFR and to 
the exclusion of one outlying within-subject measurement for iohexol clearance 
(Supplementary Table S1). Overall, no patient was completely excluded and all 
calculations of biological variation for measured and estimated GFRs were based on a 
minimum of three weeks data in all individuals. 
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Estimates of components of biological variation are given in Table 2. The geometric exact 
CVI value [95% CI] for measured GFR was 6.7% [5.6-8.2].  CVI values for the estimated 
GFR equations were broadly equivalent: MDRD 5.0% [4.3-6.1], CKD-EPIcreatinine 5.3% [4.5-
6.4], CKD-EPIcystatinC 5.3% [4.5-6.5], and CKD-EPIcreatinine+cystatinC 5.0% [4.3-6.2] to each 
other. Modelling to investigate differences showed the CVI for MDRD and CKD-
EPIcreatinine+cystatinC estimated GFRs to be significantly (at 5% level) lower than for measured 
GFR (difference -1.8%, p=0.027 and difference -1.8%, p=0.022 respectively, see 
Supplementary Table S2). Using the MDRD equation, positive and negative RCVs were 
15.1% and 13.1% respectively. For example, if baseline MDRD GFR (mL/min/1.73 m2) in 
an individual is 59, significant increases or decreases would be to values >68 or <51 
respectively. 
 
Sensitivity analyses were carried out without outlier detection and deletion. Data were 
similar to those obtained following outlier removal, with analyses after outlier removal 
estimating slightly reduced CVs (Supplementary Table S3). 
 
Modelling to identify any trends over time resulted in non-significant slopes (coef=-0.005; 
95% CI (-0.020, 0.009); p=0.488), thus providing no evidence of a change in disease state 
(kidney function) over the duration of the study. 
 
Discussion 
 
To our knowledge, this is the first study to simultaneously establish the biological variation 
of measured and estimated GFR in patients with CKD. Following a recommended study 
design,13 in a prospective study we observed the within-subject biological variation of 
measured GFR to be 6.7%, with similar, although in some cases significantly lower, 
biological variation of estimated GFR (5.0%, 5.3%, 5.3% and 5.0% for the MDRD, CKD-
EPIcreatinine, CKD-EPIcystatinC and CKD-EPIcreatinine+cystatinC equations respectively). Taking 
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analytical and within-subject biological variability into account produced RCVs (%, 
positive/negative) of 21.5/-17.7 (measured GFR), 15.1/-13.1 (MDRD), 15.9/-13.7 (CKD-
EPIcreatinine), 15.9/-13.8 (CKD-EPIcystatinC) and 15.1/-13.1 (CKD-EPIcreatinine+cystatinC).  
 
Although there have been several previous studies of the biological variation of GFR, few 
have followed the rigour of design required of a biological variation study.13, 14 
Nevertheless, several of these earlier studies report biological variability of GFR of a 
similar magnitude to that observed here, despite a variety of techniques and study 
designs; 4.5% (healthy individuals, plasma iohexol clearance),16 5.7% (CKD patients, 
plasma iohexol clearance),7 6.3% (CKD patients, renal 125I-Iothalamate clearance),8 5.5% 
(CKD patients with GFR >30 mL/min/1.73 m2, plasma 51Cr-ethylenediaminetetraacetic 
acid [EDTA] clearance),6 with some authors reporting higher estimates; 9.8% (CKD 
patients, plasma 51Cr-EDTA clearance)10 and 8.0% (CKD patients, 99mTe-DTPA 
clearance).9 Some of the differences observed may reflect the underlying level of kidney 
function in the groups studied: both Levey et al8 and Brochner-Mortensen et al6 report 
higher variation estimates in individuals with GFR<30 mL/min/1.73 m2. Other factors 
including length of time between repeat procedures (10 months) and total study duration 
(12 years),10 inattention to hydration status, fasting and exercise before and during the 
test9 may also have increased the variability reported in some studies.  
 
When considering any change in a patient’s results, healthcare practitioners need to be 
able to distinguish true change (‘signal’) from the ‘noise’ of variability. In clinical practice, 
biological variation is best considered in terms of the RCV, which takes both biological 
and analytical variation of measured GFR into account: the positive and negative RCVs of 
measured GFR were 21.5% and -17.7% respectively. Definitions of progressive kidney 
disease vary but it is important to consider whether, in the clinical context, the variability of 
measured GFR allows for detection of progressive kidney disease over a useful time 
frame. Reported ‘normal’ mean age-related decline in GFR of 1 mL/min/1.73 m2/year,17 or 
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reported rates of decline of 3.6 mL/min/1.73 m2/year and 2.8 mL/min/1.73 m2/year 
respectively in male and female community dwelling older adults with diabetes and 
moderate CKD18 could not be detected in individuals by annual GFR measurement. It is 
possible that reported annual mean GFR declines of 7.0 mL/min/1.73 m2/year amongst 
proteinuric (greater than 1 g/24 h) patients could be detected by annual monitoring of 
individual patient’s GFR.19. Importantly, based on the data presented here, monitoring of 
GFR will permit detection of progressive kidney disease as defined by recent guideline 
recommendations from Kidney Disease Improving Global Outcomes (KDIGO) and the 
National Institute for Health and Care Excellence (NICE). Both guidelines define a certain 
drop in GFR as an increase in disease category (e.g. G3a [GFR 45-59 mL/min/1.73 m2] to 
G3b [GFR 30-44 mL/min/1.73 m2]) accompanied by a fall in GFR of greater than or equal 
to 25% between two serial results. Alternatively, they define a significant change as a 
decrease in GFR of 15 mL/min/1.73 m2 or more per year.5, 20 For example: if baseline 
measured GFR in an individual is 59 mL/min/1.73 m2, significant increases or decreases 
would be to values >72 or <48 mL/min/1.73 m2. Given the lower CVI and CVA of estimated 
GFR, slightly lower RCVs may be applied when monitoring patients using GFR estimating 
equations (e.g. if an individual’s baseline MDRD estimated GFR was 59, significant 
increases or decreases would be to values >68 or <51 mL/min/1.73 m2 respectively). 
However, it must be remembered that our biological variation estimates are obtained 
under idealised conditions, with optimisation of preanalytical variables and precise 
laboratory methods. In an uncontrolled operational clinical environment, it is likely that 
biological and analytical variation, and hence RCVs, would increase.  
 
The within-subject biological variation of serum creatinine we have observed (4.4%) is in 
broad agreement with values reported in other studies in both healthy (4.1% to 7.6%,16, 21-
28) and diseased (5.7% to 9.9%23, 29-31) cohorts. Enzymatic creatinine methods are less 
prone to interference than Jaffe methods and the use of an enzymatic assay in the 
present study improves confidence in the estimate of biological variation we have 
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reported. Whilst calculation of CVI excludes any contribution due to CVA, it cannot account 
for biological variability of non-creatinine chromogens (e.g. bilirubin, glucose, ketones, 
protein, and certain drugs) that are known to interfere in Jaffe methods of creatinine 
measurement. Similarly, our reported within-subject biological variation of cystatin C 
(4.0%) is similar to most (3.1%,32 4.1%,25 4.5%16, 27 and 4.8%29) but not all (6.8%,28 8.6%23 
and 13.3%24) previous estimates. As for measured GFR, differences in study design and 
data analysis may account for differences in reported estimates of variation: for example, 
most of these studies did not report their approach to outlier detection; the time interval 
between repeat sampling was prolonged in some studies.28 
 
Depending on the equation used, estimated GFR is based on the concentration of 
creatinine, cystatin C or both. Therefore estimated GFR will have a similar CVI to 
creatinine or cystatin C, mathematically inflated by the power function in the respective 
equation. The point estimates for CVI of the four studied equations lie between 5.0% and 
5.3% and have overlapping confidence intervals. 
  
It is uncertain why the CVI of estimated GFR should be lower than that of measured GFR. 
Probably the complexity of the iohexol clearance procedure, involving multiple 
measurements and blood samplings, contributes to a higher CVI for measured than 
estimated GFR. However, it is also possible that the variability of estimated GFR is 
somewhat attenuated compared to physiological fluctuations in measured GFR, as noted, 
in an extreme example, following renal insult in acute kidney injury where there is a delay 
between the fall in GFR and the consequent rise in blood creatinine concentration.  
 
These data have implications for the use of measured versus estimated GFR in clinical 
practice and research. Within-subject biological variation of measured GFR was similar to 
that of estimated GFR, implying no disadvantage to the use of simple estimates of GFR 
when monitoring patients over time. The main priority for monitoring GFR is to detect 
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change and for this purpose estimated GFR is at least as reliable as measured GFR. This 
is important because measurement of GFR is time consuming and more costly than 
estimated GFR. However, this should not be interpreted as an indication that estimated 
GFR should replace measured GFR when an accurate assessment of GFR is required. 
Reference techniques are considered more accurate than estimated GFR primarily 
because they are not influenced by the non-GFR determinants of endogenous filtration 
markers. Reference GFR measurements will remain important as the benchmark in 
clinical research studies and to inform clinical situations in which more accurate 
knowledge of GFR is important. These situations include certain chemotherapies (e.g. 
carboplatin); the use of any drug that is nephrotoxic or renally-excreted and has a narrow 
therapeutic margin; the assessment of potential living related kidney donors; and the 
assessment of GFR in patients with muscle-wasting disorders, including spina bifida and 
paraplegia. 
 
The strengths of this study include the use of an enzymatic creatinine assay and a three-
point iohexol clearance procedure with the final sample being taken at 4 h postinjection, 
which is considered suitable for patients with GFR>30 mL/min/1.73 m2.33 The study was 
adequately powered34 and followed a strict design to minimise preanalytical variation and 
investigator bias (Supplementary Table S4).13  Outliers were excluded using a formal 
exclusion protocol: sensitivity testing was undertaken using excluded data to confirm that 
presented results were representative. Estimation of components of variation was derived 
using a nested ANOVA approach, which takes into account analytical variation for 
estimation of within-subject biological variation. The studied patient group represents a 
major population in which monitoring of kidney function to detect worsening disease is 
regularly undertaken and which is mandated in international guidance.5, 20 Prescribed 
medication was unaltered during the study, with the exception of two patients who 
received a course of amoxicillin. No patients showed significant trends in GFR during the 
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study period, confirming that the variation we have reported is physiological and not 
pathological in nature.  
 
Our study has some limitations. The cohort studied was recruited from a single centre and 
was exclusively Caucasian: biological variability estimates may not be transferable to 
other ethnic groups. Although the study was adequately powered to answer the primary 
question, we were unable to investigate whether variability is higher at differing levels of 
GFR or albuminuria. Although previous studies have observed statistically significant 
differences in CVI when individuals are stratified for level of GFR/albuminuria29 such 
effects are unlikely to be of practical importance.25 Our measured GFR data was based on 
a plasma iohexol clearance procedure. Whilst constant infusion urinary inulin clearance 
would be considered the reference measure of GFR, single-bolus plasma clearance of 
iohexol demonstrates good agreement with this technique and is widely used in clinical 
practice.35 In terms of CVI, plasma clearance techniques are likely to produce lower values 
than urinary clearance techniques due to problems of inaccurate urine collection. We have 
chosen to calculate RCVs representing 95% probability, as is conventional. However, if a 
lower probability was considered clinically acceptable, then the RCV would be smaller.22 
 
In clinical practice, in the setting of CKD identification of deterioration of kidney function 
tends to be based not upon two consecutive results but on multiple observations obtained 
over a period of time. Traditional RCV calculations only allow comparison between two 
consecutive measurements. When multiple measurements are available then use of RCV 
values as described herein will be susceptible to the effect of repeated testing, where the 
probability of a false-positive result increases with the number of results available. 
Because of this, in general terms RCV values increase with the number of observations 
available (i.e. a larger change is required compared to the baseline value to be deemed 
significant). Adjustments to the RCV calculation dependent on the number of results have 
been published but are relatively complex.36, 37 Because of this, and also because our 
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patients were being studied within relatively controlled conditions as discussed above, the 
RCV values we have reported should be considered minimum values: in clinical practice, 
for the same certainty of change, larger RCVs may be required. 
 
 
In conclusion we describe the biological variability of measured and estimated GFR in a 
carefully designed study. The data generated have implications for monitoring of patients 
with CKD and clinical ability to detect CKD progression, both in clinical practice and in 
clinical trials, whether using measured or estimated GFR. Within-subject biological 
variation of measured GFR is similar to that of estimated GFR and, in terms of variability, 
suggests no real advantage to the use of measured GFR when monitoring patients over 
time. Most importantly, the information presented provides an evidence-base allowing 
clinicians to have meaningful discussions with their patients about the implications of 
changes in their GFR results.  
 
Methods 
 
Chronic kidney disease patients (n=20) with MDRD estimated GFR between 30 and 59 
mL/min/1.73 m2 sustained over at least 90 days were recruited at the Kent Kidney Care 
Centre, UK between August 2014 and July 2015.38 Patients with diabetes and proteinuria 
(ACR >30 mg/mmol) were included in the study. Patients who had a history of reaction to 
iodinated contrast media, who were pregnant, who had an episode of acute kidney injury 
within the last six months, amputees and those with an inability to consent due to 
cognitive impairment were excluded from the study. Patients provided written informed 
consent and the study had ethical approval (South-East Coast-Surrey Research Ethics 
Committee of the National Research Ethics Service reference number 13/LO/1349). The 
study conforms to the internationally agreed checklist for the reporting of studies of 
biological variation (Supplementary Table S4).13  
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The sample size was based on the precision of CVI, which was estimated to be 10%. With 
twenty participants recruited, tested on four occasions and assayed in duplicate and 
assuming data are log-normally distributed, an approximate 95% confidence interval (CI) 
for CVI has limits ±2% (absolute).  
 
Measurement and estimation of GFR 
Patients underwent four iohexol reference measures of GFR in four successive weeks, 
with standardisation for time of day and day of week. Participants were asked to follow a 
permitted food list from 22:00 the night before the procedure, being permitted a light 
breakfast with no high protein foods on the morning of the procedure. Demographic data, 
comorbidity information and prescription histories were recorded and blood pressure, 
weight and height documented. Blood samples were taken immediately prior to iohexol 
injection for serum creatinine and cystatin C measurement. Blood samples were collected 
using standard venepuncture procedures, including the use of a tourniquet, into gel-
separator (for serum cystatin and creatinine) and lithium heparin- (for plasma iohexol) 
containing VacuetteTM tubes (Greiner Bio-One International) following manufacturer’s 
recommended order of draw. Plasma/serum was separated by centrifugation within 4 h of 
venepuncture and sample aliquots were stored at -80°C pending analysis. All analyses 
were undertaken within 9 months of venepuncture at a central laboratory. 
 
A 5 mL bolus of Omnipaque 240 (518 g/L iohexol corresponding to 240 g/L iodine, GE 
Healthcare www.gelifesciences.com) followed by 10 mL physiological saline was injected 
into the antecubital vein. A blood sample was taken at 5 minutes from the opposite arm to 
confirm that the iohexol had been administered intravenously. Further blood samples were 
collected at 120, 180 and 240 minutes after injection. Exact times of blood draws in 
relation to injection time were recorded. During the procedure individuals were allowed 
   
  14 
free access to fluids (no carbonated drinks), but asked to refrain from protein intake and 
excessive exercise. 
 
Detailed laboratory methods are available in the supplementary file. Briefly, iohexol was 
measured using electrospray isotope dilution tandem mass spectrometry. Iohexol 
concentrations were log transformed (natural log) and plotted as a function of time. GFR 
was calculated from the slope-intercept method using a single compartment model,  
GFR (mL/min) = 0.693 x iohexol volume of distribution (L) x 1000/half-life of iohexol (min). 
GFR was adjusted for body surface area (BSA)39 and then corrected for the fast 
exponential.40 
 
Serum creatinine was measured using an enzymatic assay standardised to the reference 
material, NIST SRM 967 and 914. Between-day imprecision (coefficient of variation, %) 
was 0.8%, 0.3% and 0.4% at concentrations of 75, 176 and 760 umol/L respectively. 
Cystatin C was measured by a turbidimetric immunoassay calibrated against the 
international certified reference material ERM-DA471/IFCC for cystatin C.41 GFR was 
estimated using the simplified isotope dilution mass-spectrometric (ID-MS) traceable 
version of the MDRD equation42 and the three CKD-EPI equations: CKD-EPIcreatinine, CKD-
EPIcystatinC and CKD-EPIcreatinine-cystatinC.43, 44 
 
Statistical analysis 
Data were log-transformed and normality tests were performed using the Shapiro-Wilk 
test. Outliers between duplicate measurements and of within-subject variance were 
excluded using Cochran’s test and outliers amongst mean values of subjects were 
excluded using Reed’s test as advocated by Fraser and Harris.14 Sensitivity analyses 
were also performed without exclusion of identified outliers. Log transformation was used 
to simplify calculation and because it improved the normality of the data as assessed by 
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an increase in Shapiro–Wilk W statistic and visual examination of the distributions 
(Supplementary Figure S1 and Table S5).  
 
Terminology used was as proposed by Simundic et al.45 Analytical (CVA), CVI and 
between-subject (CVG) components of variation were calculated using standard 
approaches14 of linear random effects modelling with restricted maximum likelihood 
estimation (allowing for the clustering of observations within time points and repeated 
observations per patient) (Stata version 15). Exact geometric CVs [√exp(S2) − 1 × 100,46, 
47] were calculated. Confidence intervals for SDs and CVs were estimated as described by 
Burdick and Graybill.48  Differences in measures of CV, comparing the estimated GFR 
measures to measured GFR were investigated using multilevel models accounting for the 
clustering of test observations within individuals, using unstructured covariance matrices, 
in addition to the clustering of test results (multiple results per person, observation points 
and assessments). The RCV for a change in GFR between two results with 95% 
probability was calculated using the approach for log-normal data giving a negative and 
positive limit.49 The number of specimens (n) required to produce a precise estimate of the 
homeostatic set-point with 95% confidence within +10% was calculated as: 
 
n = [1.96(CVI2 + CVA2)1/2/10]2 
 
For each biomarker the index of individuality (II) was calculated as: 
 
II = (CVI2 + CVA2)1/2/CVG 
 
To confirm kidney function was stable across the study period, the iohexol GFR measures 
were modelled to identify trend with time using a multilevel linear regression model 
(allowing for clustering of assessments within time points and observations within 
individuals). 
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Table 1. Characteristics of the study population. Values for continuous data are shown 
as median (range). Anthropometric data is based on baseline measurements. Estimated 
and measured* GFR, creatinine and cystatin C data are calculated using all values over 
the four weeks. 
 
n 20 
Age, y 71 (50-80) 
M:F 10:10 
Caucasian (n) 20 
Height, cm 170.5 (154-194) 
Weight, kg 79.5 (47.1-118.1) 
Body surface area, m2 1.99 (1.42-2.47) 
Body mass index, kg/m2 28.2 (19.6-40.9) 
Medication record (n) Thiazide diuretic (3), loop diuretic (3), 
potassium sparing diuretic (2), beta-
blocker (7), calcium antagonist (4), ACE 
inhibitor (8), angiotensin 2 receptor 
blocker (6), alpha-blocker (1), isosorbide 
mononitrate (1), HMG CoA reductase 
inhibitor (13), allopurinol (4), antiplatelet 
drugs (7)   
Comorbidity (n) Type 2 diabetes mellitus (3), ischaemic 
heart disease (7), angina (1), heart 
failure (2) 
 
Smoker – current/former (n) 1/10 
Urine albumin concentration <3 mg/mmol (n) 9 
Urine albumin concentration 3-30 mg/mmol (n) 7 
Urine albumin concentration >30 mg/mmol (n) 4 
Serum creatinine, µmol/L 124 (79-182) 
Serum cystatin C, mg/L 1.67 (1.01-2.30) 
Measured GFR, mL/min/1.73 m2 49.0 (30.8-71.6)* 
MDRD, mL/min/1.73 m2   42.2 (31.5-61.4) 
CKD-EPIcreatinine, mL/min/1.73 m2 43.0 (30.8-62.8) 
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CKD-EPIcystatinC, mL/min/1.73 m2 36.8 (23.5-67.1) 
CKD-EPIcreatinine+cystatinC, mL/min/1.73 m2 38.2 (27.2-65.4) 
 
Abbreviations: ACE, angiotensin converting enzyme; CKD-EPI, Chronic Kidney Disease 
Epidemiology Collaboration; HMG, hydroxymethyl glutaryl; MDRD, Modification of Diet in 
Renal Disease 
*Excludes data from five failed iohexol procedures (five separate patients). 
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Table 2. Summary of components of variation for creatinine and cystatin C and measured and estimated glomerular filtration rate (GFR) 
 
    Estimated GFR 
 Measured GFR Creatinine Cystatin C 
MDRD CKD-EPIcreatinine CKD-EPICystatinC 
CKD-
EPIcreatinine+CystatinC 
Geometric exact       
CVA (%) 2.3 (1.9, 2.7) 0.7 (0.6, 0.8) 0.6 (0.5, 0.7) 0.8 (0.7, 0.9) 0.8 (0.7, 1.0) 0.7 (0.6, 0.9) 0.6 (0.5, 0.7) 
CVI (%) 6.7 (5.6, 8.2) 4.4 (3.7, 5.3) 4.0 (3.4, 4.9) 5.0 (4.3, 6.1) 5.3 (4.5, 6.4) 5.3 (4.5, 6.5) 5.0 (4.3, 6.2) 
CVG (%) 16.7 (12.5, 24.9) 20.0 (15.0, 29.6) 19.0 (14.4, 28.2) 17.8 (13.4, 26.0) 19.3 (15.5, 29.2) 25.2(18.9, 37.5) 20.2 (15.2, 30.0) 
        
Positive RCV (%) 21.5 13.0 11.8 15.1 15.9 15.9 15.1 
Negative RCV (%) -17.7 -11.5 -10.6 -13.1 -13.7 -13.8 -13.1 
Homeostatic set 
point 
2 1 1 1 1 1 1 
Index of 
Individuality  
0.4 0.2 0.2 0.3 0.3 0.2 0.3 
 
 
All CV values expressed as percentages. 95% confidence intervals were calculated using methods of Burdick and Graybill.48    
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CVA, analytical variation; CVG, between-subject variation; CVI, 
within-subject biological variation; MDRD, Modification of Diet in Renal Disease; RCV, reference change value
   
  27 
 
 
 
   
  1 
 
Supplementary File 
 
Biological variation of measured and estimated glomerular filtration rate (GFR) in 
patients with chronic kidney disease: the eGFR-C Study  
 
Ceri Rowe,1* Alice J Sitch,2, 3* Jonathan Barratt,4 Elizabeth A Brettell,5 Paul Cockwell,6 R 
Neil Dalton,7 Jon J Deeks,2, 3, 5 Gillian Eaglestone,8 Tracy Pellatt-Higgins,9 Philip A Kalra,10 
Kamlesh Khunti,11 Fiona C Loud,12 Frances S Morris,8 Ryan S Ottridge,5  Paul E Stevens,8 
Claire C Sharpe,13 Andrew J Sutton,14 Maarten W Taal,15  Edmund J Lamb,1** on behalf of 
the eGFR-C study group. 
 
*joint first authors 
**corresponding author 
 
1Clinical Biochemistry, East Kent Hospitals University NHS Foundation Trust, Canterbury, 
Kent, CT1 3NG, UK, 2Test Evaluation Research Group, University of Birmingham, 
Birmingham B15 2TT, UK, 3NIHR Birmingham Biomedical Research Centre, University of 
Birmingham and University Hospitals Birmingham NHS Foundation Trust, B15 2TT, UK 
4University Hospitals of Leicester, 5Birmingham Clinical Trials Unit, Institute of Applied 
Health Research, University of Birmingham, Birmingham B15 2TT UK, 6Renal Medicine, 
Queen Elizabeth Hospital Birmingham and Institute of Inflammation and Ageing, 
University of Birmingham, Birmingham B15 2TT UK, 7Evelina London Children’s Hospital, 
London SE1 7EH, 8Kent Kidney Care Centre, East Kent Hospitals University NHS 
Foundation Trust, Canterbury, Kent, CT1 3NG, UK, 9Centre for Health Services Studies, 
University of Kent, Canterbury, CT2 7NF, UK, 10Salford Royal NHS Foundation Trust, 
Salford, M6 8HD, UK 11University of Leicester, 12Kidney Care UK, 3 The Windmills, Turk 
Street, Alton, Hampshire, GU34 1EF, UK, 13King's College London & King's College 
Hospital NHS Foundation Trust, London, SE5 9RJ, 14Leeds Institute of Health Sciences, 
University of Leeds, Leeds, LS2 9JT, 15Royal Derby Hospital, Uttoxeter Road, Derby, 
DE22 3NE, UK.  
 
Address correspondence to: Dr Edmund Lamb, Consultant Clinical Scientist, Clinical 
Biochemistry, East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury 
Hospital, Canterbury, Kent, UK, CT1 3NG. Telephone: 01227 864112, Facsimile: 01227 
783077, E-mail: elamb@nhs.net 
 
   
  2 
Table of contents 
 
1. Detailed laboratory methods 
2. Figure S1. Effect of log transformations on distributions. 
3. Table S1. Identification of outliers by Cochran’s and Reed’s criterion. 
4. Table S2: Differences between measures using each GFR estimate compared 
with measured GFR (calculated as eGFR-mGFR). 
5. Table S3. Summary of components of variation for creatinine and cystatin C and 
measured and estimated glomerular filtration rate (GFR) without outlier detection 
and removal. 
6. Table S4: Critical appraisal checklist for studies of biological variation.  
7. Table S5: Shapiro-Wilk normality test p-values before and after log transformation. 
8. References for supplementary file. 
 
Detailed laboratory methods 
 
Iohexol was measured using electrospray isotope dilution tandem mass spectrometry on 
an ABSCIEX API6500 Q-trap (ABSCIEX, Warrington, UK). Iohexol stock standard, 10 
mmol/L, was prepared by diluting Omnipaque 300 solution (647 g/L) in deionised water 
and stored in 1 mL aliquots at -80oC. Aqueous iohexol calibrators (0, 10, 100 and 500 
µmol/L) were prepared from the stock iohexol standard by dilution and stored in 0.5 mL 
aliquots at -80oC. Iohexol stable isotope, d5-iohexol (Toronto Research Chemicals), was 
obtained from 2BScientific Ltd, Upper Heyford, UK, dissolved in deionised water at circa 
10 mmol/L, and stored at -80oC. Plasma control samples were prepared by spiking a 
plasma pool with iohexol stock standard at 10, 100, and 400 µmol/L. Calibrators, controls, 
patient samples and stable isotope stock solutions were thawed from frozen on a roller 
mixer at room temperature for no more than 60 minutes, and then centrifuged for 4 
minutes at 1,500 g at 4°C (Eppendorf 5810R centrifuge, VWR International Ltd, 
Lutterworth, UK). Working iohexol stable isotope was prepared by diluting the circa 10 
mmol/L solution 1:200 with deionised water. Calibrators, controls, and samples were 
pipetted (20 µL) into 2 mL microcentrifuge tubes (000-MICR-200, Elkay Laboratory 
Products (UK) Ltd, Basingstoke, UK) and 50 µL working iohexol stable isotope, followed 
by 200 µL acetonitrile (Rathburn Chemicals Ltd, Walkerburn, UK), were added to each 
tube. Samples were capped, vortex mixed for 5 seconds and centrifuged for 5 minutes at 
20,800 g at 4°C (Eppendorf 5417R centrifuge, VWR International Ltd, Lutterworth, UK). 
Supernatants (200 µL) were then transferred into a 96 deep well plate and loaded onto the 
autosampler. Sample (2 µL) was automatically injected into a mobile phase stream of 
acetonitrile:water (1:1) with 0.025% formic acid using a Hewlett-Packard 1100 Series 
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autosampler and pump (Applied Biosystems, Warrington, UK) at 250 µL/min. 
Chromatography was performed on a Chirobiotic T 100 x 2.1 mm column with a 2 cm x 
4.0 mm guard column (Sigma-Aldrich Company Ltd, Poole, UK). 
 
Tandem mass spectrometry was performed in positive ion multiple reaction monitoring 
(MRM) mode: iohexol 821.849/602.8, d5-iohexol 826.849/607.8. Data acquisition time 
was 6 minutes with a pause time of 5.0070 msec between transitions and a scan speed of 
10 Da/s. Iohexol concentrations were calculated in Analyst 1.6 (ABSCIEX, Warrington, 
UK) using the ratio of sample peak area to stable isotope peak area. Between-day 
imprecision (coefficient of variation, %) was 1.0%, 0.8% and 1.5% at 10, 100 and 400 
umol/L respectively. The laboratory participated in an international proficiency testing 
scheme (EQUALIS, https://www.equalis.se/en/start/) for iohexol measurement with 
satisfactory performance.  
 
Iohexol concentrations were log transformed (natural log) and plotted as a function of 
time. GFR was calculated from the slope-intercept method using a single compartment 
model,  
GFR (mL/min) = 0.693 x iohexol volume of distribution (L) x 1000/half-life of iohexol (min). 
GFR was adjusted for body surface area (BSA)1 and corrected for the fast exponential.2  
 
Serum creatinine was measured using an enzymatic assay on an Abbott Architect 
analyser (Abbott Diagnostics Ltd, www.international.abbottdiagnostics.com) standardised 
to the reference material, NIST SRM 967 and 914. Between-day imprecision (coefficient 
of variation, %) was 0.8%, 0.3% and 0.4% at concentrations of 75, 176 and 760 umol/L 
respectively. The laboratory participated in an international proficiency testing scheme 
(UKNEQAS, https://birminghamquality.org.uk/) for creatinine measurement and GFR 
estimation with satisfactory performance. Cystatin C was measured by a turbidimetric 
immunoassay on an Abbott Architect analyser. The assay was calibrated against the 
international certified reference material ERM-DA471/IFCC for cystatin C.3 Between-day 
imprecision was 2.3% and 1.6% at concentrations of 0.9 and 4.0 mg/L respectively. The 
laboratory participated in an international proficiency testing scheme (EQUALIS, 
https://www.equalis.se/en/start/) for cystatin C measurement and GFR estimation with 
satisfactory performance. 
 
Prior to analysis, samples were thawed at room temperature, mixed by inversion and 
centrifuged. All samples from each individual subject were measured in duplicate in 
random order in a single assay. Each of the biomarker analyses was undertaken by a 
single operator blinded to participant data using a single instrument. Creatinine and 
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cystatin C measurements were undertaken in an accredited laboratory by scientists 
registered with the Health and Care Professions Council.  
 
GFR was estimated using the simplified isotope dilution mass-spectrometric (ID-MS) 
traceable version of the MDRD equation4 and the three CKD-EPI equations: CKD-
EPIcreatinine, CKD-EPIcystatinC and CKD-EPIcreatinine-cystatinC.5,6 
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Supplementary Figure 1 – effect of log transformations on distributions  
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Supplementary Table S1. Identification of outliers by Cochran’s and Reed’s criterion. Outliers removed shown as patient ID (week of 
sample, A to D)  
 
Marker Outlier amongst duplicate 
measurements 
 
Outlier in within-subject 
measurements 
Outlier in measurements 
between subjects 
Serum creatinine (enzymatic) B10561 (B), B14944 (C),  N/A N/A 
Serum cystatin C B10561 (B), B12450 (C), B14944 (D) N/A N/A 
MDRD B10561 (B), B14944 (C) N/A N/A 
CKD-EPIcreatinine B10561 (B), B14944 (C) N/A N/A 
CKD-EPIcystatinC B10561 (B), B12450 (C), B14944 (D) N/A N/A 
CKD-EPIcreatinine+cystatinC B10561 (B) N/A N/A 
Plasma iohexol clearance B10561 (A), B14605 (C), B14944 (C) B15222 (C) N/A 
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; MDRD, Modification of Diet in Renal Disease 
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Supplementary Table S2: Differences between measures using each GFR estimate compared with measured GFR (calculated as eGFR-mGFR). 
Differences estimated using further modelling which was a paired analysis to tests differences in CVs between tests. 
 
 MDRD CKD-EPIcreatinine CKD-EPICystatinC CKD-EPIcreatinine+CystatinC 
 diff 95% CI* p diff 95% CI* p diff 95% CI* p diff 95% CI* p 
𝜎𝐺 0.013 (-0.047, 0.073) 0.665 0.027 (-0.030, 0.085) 0.351 0.084 (0.028, 0.140) 0.003 0.039 (-0.003, 0.081) 0.072 
𝜎𝐼 -0.018 (-0.033, -0.002) 0.027 -0.015 (-0.031, 0.001) 0.058 -0.015 (-0.031, 0.001) 0.063 -0.018 (-0.034, -0.003) 0.021 
𝜎𝐴 -0.015 (-0.018, -0.011) <0.001 -0.014 (-0.018, -0.010) <0.001 -0.015 (-0.019, -0.011) <0.001 -0.017 (-0.020, -0.013) <0.001 
             
Geometric 
exact             
𝐶𝑉𝐺  (%) 1.35 (-4.76, 7.46) 0.665 2.79 (-3.08, 8.67) 0.351 8.64 (2.79, 14.49) 0.004 3.97 (-0.37, 8.32) 0.073 
𝐶𝑉𝐼  (%) -1.77 (-3.33, -0.20) 0.027 -1.54 (-3.13, 0.05) 0.058 -1.49 (-3.06, 0.08) 0.063 -1.82 (-3.37, -0.27) 0.022 
𝐶𝑉𝐴 (%) -1.46 (-1.84, -1.07) <0.001 -1.42 (-1.81, -1.03) <0.001 -1.48 (-1.86, -1.10) <0.001 -1.65 (-2.03, -1.27) <0.001 
             
 
*95% confidence intervals (in brackets) were calculated using the delta method and may be conservative.  Note that differences will not be the same as 
differences between estimates for each test individually as differences here have been calculated using a paired analysis. 
 
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CVA, analytical variation; CVG, between-subject variation; CVI, within-subject 
biological variation; MDRD, Modification of Diet in Renal Disease; RCV, reference change value
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Supplementary Table S3. Summary of components of variation for creatinine and cystatin C and measured and estimated glomerular 
filtration rate (GFR) without outlier detection and removal 
    Estimated GFR 
 GFR Creatinine Cystatin C 
MDRD CKD-EPIcreatinine CKD-EPICystatinC 
CKD-
EPIcreatinine+CystatinC 
Geometric exact       
CVA (%) 2.4 (2.1, 2.8) 0.7 (0.6, 0.8) 0.60 (0.52, 0.71) 0.8 (0.7, 0.9) 0.8 (0.7, 0.9) 0.8 (0.7, 0.9) 0.6 (0.5, 0.7) 
CVI (%) 6.9 (5.8, 8.5) 4.3 (3.7, 5.3) 4.0 (3.4, 4.9) 5.0 (4.2, 6.1) 5.2 (4.4, 6.4) 5.3 (4.5, 6.5) 5.0 (4.3, 6.1) 
CVG (%) 16.4 (12.2, 25.6) 20.1 (15.2, 29.8) 19.0 (14.3, 28.1) 17.8 (13.5, 26.6) 19.4 (14.6, 28.8) 25.1 (18.9, 37.4) 20.2 (15.2, 30.0) 
        
Positive RCV (%) 22.5 12.9 11.8 15.0 15.7 16.0 15.0 
Negative RCV (%) -18.3 -11.4 -10.6 -13.0 -13.6 -13.8 -13.1 
Homeostatic set 
point 
2 1 1 1 1 1 1 
Index of 
Individuality  
0.5 0.2 0.2 0.3 0.3 0.2 0.3 
 
All CV values as expressed as percentages. 95% confidence intervals (in brackets) were calculated using methods of Burdick and Graybill. 7    
  
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CVA, analytical variation; CVG, between-subject variation; CVI, 
within-subject biological variation; MDRD, Modification of Diet in Renal Disease; RCV, reference change value 
  
   
  9 
Supplementary Table S4: Critical appraisal checklist for studies of biological variation8 
 
Section and 
Topic 
Item # 
 
Evidenced 
Title/abstract/ 
keywords 
1 The title should indicate that the content relates to a study of 
biological variation, the subject of the study, the sample matrix, 
and the population studied. Analyte (component being 
measured), the measurand/s (the quantity or quantities to be 
measured), and state of well-being of the subjects under study 
should be clearly and unambiguously identified. Relevant coding 
systems might be employed, (e.g., LOINC, SNOMED, C-NPU) 
Title: Biological variation of measured and 
estimated glomerular filtration rate (GFR) in 
patients with chronic kidney disease: the eGFR-C 
Study. 
Abstract 1.1 As a minimum it should contain the headline biological variation 
data, the major characteristics of the population studied (numbers 
of subjects with demographics), clearly identify the analyte and 
measurand/s studied [the analyte quantities studied in a particular 
sample matrix, (e.g., concentration of glucose in plasma)], the 
statistical approach taken, the duration of the study and the 
geographical location of the study. 
The abstract includes all required information, 
except that geographical setting is given in 
methods section due to space constraints in 
abstract. 
Introduction 2 Introduction should clearly identify the context and aims of the 
study and cite any previous relevant studies of biological 
variability of the target analyte. Recommended terminology to be 
adopted re description of variability.9 
The introduction addresses these points. Previous 
relevant studies are cited. Appropriate 
recommended terminology is used.9 
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Methods 3 Described in enough detail to facilitate transportability of the 
derived data across populations and health care systems. The 
biological variation data produced are effectively reference data 
and their applicability requires delivery of appropriately described 
metadata to enable their use as such. 
Methods are given within the main manuscript with 
more detailed laboratory methods provided within 
the supplementary file. 
Analyte/ 
measurand 
3.1 The described study should clearly identify the target analyte and 
measurand/s. Where available internationally agreed terminology 
and codings should be utilised. 
Detailed descriptions of the methods used to 
measure iohexol, creatinine and cystatin C, and of 
the use of these measurements in estimating and 
measuring GFR are given. 
Subjects 3.2 The description of the subjects and population studied should be 
detailed enough to enable transportability of the biological 
variation data. Minimum data set should be present. This should 
include number of subjects studied, age, gender, and state of 
well-being. 
The subjects and population are described in the 
methods section and in table 1. 
Measurement 
procedure 
3.3 A clear description of the analytical methodology used should 
form part of the metadata. This may be made available via an 
appropriate reference or be presented within the publication. 
Deviation from standard operating procedures, use of adaptations 
of published methods, and deviation from manufacturers 
recommended methods in the case of commercially available 
systems should be documented. Standardisation and traceability 
should be clearly identified. 
See Methods section in main paper and detailed 
analytical methods in supplementary file. Details of 
standardisation are given. 
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Length of study 3.4 Length of the study periods should be clearly identified. Stated in methods section. 
Sampling 3.5 Sampling protocols (e.g., subject preparation, sampling 
conditions) that minimise pre-analytical variation should be 
adequately described to enable transportability of the data.10  
Numbers of samples taken should be sufficient to deliver the 
required power to the study.10,11 
Minimisation of preanalytical variables is clearly 
described in methods section. Power of study was 
adequate and is addressed in the discussion. 
Samples 3.6 Recorded details should include the beginning and end date of 
the study and timings of sampling. Sampling conditions and 
sample type should be described in detail. Pre-analytical storage 
conditions of samples should be described. 
See methods section. 
Conditions for 
analysis of 
samples 
3.7 A description of conditions under which the samples were 
analysed. Analytical protocols should be designed to minimise 
sources of analytical variation (Optimal Conditions Precision). 
See methods section and detailed methods in 
supplementary file. Analytical imprecision is 
presented and was <2.4% in all cases. 
Data analysis 4 Data analysis techniques should be described. The power of the 
study to identify indices of biological variation should be 
calculated and presented.11 
See methods/data analysis section. 
Outlier analysis 4.1 Outliers should be excluded from the final analysis of the data. 
Test for outliers should be applied to all levels of data (between 
replicate analysis, between samples within subject, between 
subjects).10 The numbers of outliers and reasons for their 
Outlier exclusion is clearly described in the 
methods section and in more detail in 
supplementary table S1. An analysis without outlier 
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exclusion must be given. removal is given in supplementary table S3. 
Heterogeneity of 
variance 
4.2 Subjects with outlying within subject variance should be rejected 
from calculations used to determine an estimate of common true 
variance. The numbers of outliers and reasons for their exclusion 
must be given. 
One outlier for within subject variance for iohexol 
clearance was removed (supplementary table S1). 
Statistical 
methods 
described and 
appropriate 
4.3 Statistical methods used should be appropriately identified, fit for 
purpose and referenced. Data that do not conform to a normal 
distribution should be appropriately transformed.10 
Statistical methods are described in the methods 
section. Data were not normally distributed. Log 
transformation was used to simplify calculation and 
because it improved the normality of the data as 
assessed by an increase in Shapiro–Wilk W 
statistic and visual examination of the distributions 
(supplementary figure S1 and table S5). 
Results 5 Unified terminology9 should be used and appropriately defined 
metadata clearly presented to enable understanding and 
transportation of the data through time and across health care 
systems. 
Recommended terminology used throughout.  
Terminology 5.1 Terms and symbols should be used to describe biological 
variation should conform to standards identified by Simundic et 
al.9 
Recommended terms and symbols used 
throughout. 
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Results clearly 
presented and 
managed 
5.2 Biological variation data, with derived indices, should be 
tabulated in a format that enables extraction of the key data 
unambiguously associated with a minimum data set to enable 
transportability of the data. 
Power of the study and confidence limits around estimates of 
biological variation should be presented.11 
The results section should clearly identify the results of outlier 
analysis undertaken and confirm homogeneity of the data sets. 
If data are stratified the variables used to enable this should be 
clearly characterised. 
Table 2 summarises components of variation. 
Power of the study was confirmed using the 
recommended approach. 11 Confidence limits for 
data are given in Table 2. Outlier analysis is clearly 
described in the results section and in more detail 
in supplementary table S1. An analysis without 
outlier removal is given in supplementary table S3. 
Discussion 6 The discussion of the data should clearly include a focus on 
factors that impact on the transportability of the data to other 
settings. Limitations and strengths of the study should be 
addressed. 
If the data are used to set analytical performance specifications, 
derive reference change values and study individuality, the 
recommendations of Simundic et al. should be followed.9 
Strengths and limitations of the study are 
addressed in the discussion. The focus of the 
study was not primarily to derive analytical 
performance specifications. 
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Supplementary Table S5: Shapiro-Wilk normality test p-values before and after log transformation 
  
  
  
 Measured GFR  MDRD  CKD-EPIcreatinine CKD-EPIcystatin C  CKD-
EPIcreatinine+cystatinC 
 
Untransformed 0.00038  
   
0.00002 0.00002 <0.00001 <0.00001 
Log transformed 0.11279 0.00037 0.00026 0.00106 0.00045 
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